Skip to Content

Oncology Pharma Inc ONPH

Morningstar Rating
$0.00 0.00 (99.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ONPH is trading at a 54% discount.
Price
$0.00
Fair Value
$1.64
Uncertainty
Extreme
1-Star Price
$1.19
5-Star Price
$9.43
Economic Moat
Ggl
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ONPH is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.001.05
Bid/Ask
$0.25 / $0.30
Market Cap
$37.96
Volume/Avg
250 / 3,832

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Oncology Pharma Inc is engaged in the development, manufacturing, and commercialization of therapeutics. Its NanoSmart's platform technology is a human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in solid tumors. The company is developing a novel drug delivery vehicle that targets many types of cancer.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
18

Valuation

Metric
ONPH
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
ONPH
Quick Ratio
0.09
Current Ratio
0.09
Interest Coverage
Quick Ratio
No chart available

Profitability

Metric
ONPH
Return on Assets (Normalized)
−316.08%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
No chart available
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRXmnjxjfhMdhx$558.5 Bil
VRTX
Vertex Pharmaceuticals IncPjrwcjgvHwftf$103.4 Bil
REGN
Regeneron Pharmaceuticals IncTtlfsmmpGlgbzz$102.8 Bil
MRNA
Moderna IncXkjqfrpylDdjx$41.0 Bil
BNTX
BioNTech SE ADRJwhkgyzvBjkp$21.7 Bil
ALNY
Alnylam Pharmaceuticals IncXpypnmtqSvnpwtm$19.7 Bil
BMRN
Biomarin Pharmaceutical IncTybthphfWdgyvd$17.4 Bil
RPRX
Royalty Pharma PLC Class APdjfpgqrlKtxpyg$13.0 Bil
INCY
Incyte CorpLnmxhmbrVqytrp$12.4 Bil
UTHR
United Therapeutics CorpHcrdqygtRrqk$11.2 Bil

Sponsor Center